Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US7612072B2 · kind B2 · utility
8Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 9, 2005 |
| Grant date | Nov 3, 2009 |
| Priority date | — |
| Expiry date | Aug 10, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I as well as a process for its preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.